Literature DB >> 10200298

Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression.

L M McGregor1, B K McCune, J R Graff, P R McDowell, K E Romans, G D Yancopoulos, D W Ball, S B Baylin, B D Nelkin.   

Abstract

Although initiating mutations in the ret protooncogene have been found in familial and sporadic medullary thyroid carcinoma (MTC), the molecular events underlying subsequent tumor progression stages are unknown. We now report that changes in trk family neurotrophin receptor expression appear to be involved in both preneoplastic thyroid C cell hyperplasia and later tumor progression. Only a subset of normal C cells expresses trk family receptors, but, in C cell hyperplasia, the affected cells consistently express trkB, with variable expression of trkA and trkC. In later stages of gross MTC tumors, trkB expression was substantially reduced, while trkC expression was increased and often intense. In a cell culture model of MTC, exogenous trkB expression resulted in severely impaired tumorigenicity and was associated with 11-fold lower levels of the angiogenesis factor vascular endothelial growth factor. These results suggest that trk family receptor genes participate in MTC development and progression, and, in particular, that trkB may limit MTC tumor growth by inhibition of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200298      PMCID: PMC16368          DOI: 10.1073/pnas.96.8.4540

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

2.  trkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors.

Authors:  D S Middlemas; R A Lindberg; T Hunter
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

3.  Molecular and biochemical characterization of the human trk proto-oncogene.

Authors:  D Martin-Zanca; R Oskam; G Mitra; T Copeland; M Barbacid
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

4.  C-cell hyperplasia preceding medullary thyroid carcinoma.

Authors:  H J Wolfe; K E Melvin; S J Cervi-Skinner; A A Saadi; J F Juliar; C E Jackson; A H Tashjian
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

5.  Age-related probability of development of hereditary medullary thyroid carcinoma.

Authors:  R F Gagel; C E Jackson; M A Block; Z T Feldman; S Reichlin; B P Hamilton; A H Tashjian
Journal:  J Pediatr       Date:  1982-12       Impact factor: 4.406

6.  Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells.

Authors:  T Nakagawa; M Mabry; A de Bustros; J N Ihle; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells.

Authors:  E Lucarelli; D Kaplan; C J Thiele
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

8.  The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase.

Authors:  S M Lippman; G Mendelsohn; D L Trump; S A Wells; S B Baylin
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

9.  Risk estimation and screening in families of patients with medullary thyroid carcinoma.

Authors:  B A Ponder; M A Ponder; R Coffey; M E Pembrey; R F Gagel; M Telenius-Berg; P Semple; D F Easton
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

10.  Inherited medullary thyroid carcinoma: a final monoclonal mutation in one of multiple clones of susceptible cells.

Authors:  S B Baylin; S H Hsu; D S Gann; R C Smallridge; S A Wells
Journal:  Science       Date:  1978-01-27       Impact factor: 47.728

View more
  41 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

2.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

Review 3.  Serum markers of hepatocellular carcinoma.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Massimiliano Berretta; Alessandro Cappellani; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2010-03-26       Impact factor: 3.199

Review 4.  RET TKI: potential role in thyroid cancers.

Authors:  Alessandro Antonelli; Poupak Fallahi; Silvia Martina Ferrari; Caterina Mancusi; Michele Colaci; Libero Santarpia; Clodoveo Ferri
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 5.  Cardiovascular actions of neurotrophins.

Authors:  Andrea Caporali; Costanza Emanueli
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

Review 6.  On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.

Authors:  Carol J Thiele; Zhijie Li; Amy E McKee
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

7.  Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Authors:  Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

8.  High-affinity neurotrophin receptors and ligands promote leukemogenesis.

Authors:  Zhixiong Li; Gernot Beutel; Mathias Rhein; Johann Meyer; Christian Koenecke; Thomas Neumann; Min Yang; Jürgen Krauter; Nils von Neuhoff; Michael Heuser; Helmut Diedrich; Gudrun Göhring; Ludwig Wilkens; Brigitte Schlegelberger; Arnold Ganser; Christopher Baum
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

9.  Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma.

Authors:  Tomonori Sasahira; Nobuhiro Ueda; Kazuhiko Yamamoto; Ujjal K Bhawal; Miyako Kurihara; Tadaaki Kirita; Hiroki Kuniyasu
Journal:  Clin Exp Metastasis       Date:  2012-08-12       Impact factor: 5.150

10.  Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma.

Authors:  Guido Rasi; Annalucia Serafino; Lia Bellis; Maria Teresa Lonardo; Federica Andreola; Manuela Zonfrillo; Giovanni Vennarecci; Pasquale Pierimarchi; Paola Sinibaldi Vallebona; Giuseppe Maria Ettorre; Eugenio Santoro; Claudio Puoti
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.